Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 12/20 | 0.63 |
| ▸ | THRA | P10827 | 11/20 | 0.63 |
| ▸ | THRB | P10828 | 11/20 | 0.63 |
| ▸ | BBOX1 | O75936 | 2/20 | 0.51 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | ASPH | Q12797 | 1/20 | 0.47 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31028950 | 1.00 | EGLN1 (0.63) | EGLN1THRATHRBBBOX1FTO | |
| SCHEMBL522397 | 0.84 | EGLN1 (0.70) | EGLN1THRATHRBBBOX1FTO | |
| SCHEMBL522581 | 0.84 | EGLN1 (0.69) | EGLN1THRATHRBBBOX1FTO | |
| SCHEMBL522183 | 0.82 | EGLN1 (0.64) | EGLN1THRATHRBBBOX1FTO | |
| SCHEMBL523120 | 0.82 | EGLN1 (0.67) | EGLN1THRATHRBBBOX1FTO | |
| SCHEMBL523060 | 0.82 | EGLN1 (0.67) | EGLN1THRATHRBBBOX1FTO | |
| SCHEMBL22288649 | 0.81 | EGLN1 (0.65) | EGLN1THRATHRBBBOX1FTO | |
| SCHEMBL522425 | 0.80 | EGLN1 (0.71) | EGLN1THRATHRBBBOX1FTO | |
| SCHEMBL522017 | 0.80 | EGLN1 (0.72) | EGLN1THRATHRBBBOX1FTO | |
| SCHEMBL523787 | 0.78 | EGLN1 (0.58) | EGLN1THRATHRBBBOX1FTO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10548860-B2 | HIF-1 modulator paint formulation and uses thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-02-04 | — | — | US | disclosed |
| US-20190192452-A1 | HIF-1 MODULATOR PAINT FORMULATION AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2019-06-27 | — | — | US | disclosed |
| US-10220009-B2 | HIF-1 modulator paint formulation and uses thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2019-03-05 | — | — | US | disclosed |
| US-10098857-B2 | Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2018-10-16 | — | — | US | disclosed |
| US-20170281570-A1 | TOPICAL AND TRANSDERMAL DELIVERY OF HIF-1 MODULATORS TO PREVENT AND TREAT CHRONIC WOUNDS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-10-05 | — | — | US | disclosed |
| US-9763899-B2 | Iron chelators and use thereof for reducing transplant failure during rejection episodes | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2017-09-19 | — | — | US | disclosed |
| US-20170252310-A9 | Iron Chelators and Use Thereof for Reducing Transplant Failure During Rejection Episodes | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-09-07 | — | — | US | disclosed |
| US-20160184244-A1 | Iron Chelators and Use Thereof for Reducing Transplant Failure During Rejection Episodes | UNIV LELAND STANFORD JUNIOR (US) | 2016-06-30 | — | — | US | disclosed |
| US-20150196512-A1 | HIF-1 Modulator Paint Formulation and Uses Thereof | THE JOHNS HOPKINS UNIVERSITY | 2015-07-16 | — | — | US | disclosed |
| WO-2014100233-A1 | IRON CHELATORS AND USE THEREOF FOR REDUCING TRANSPLANT FAILURE DURING REJECTION EPISODES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014036414-A2 | IRON CHELATORS AND USE THEREOF FOR REDUCING TRANSPLANT FAILURE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2014-03-06 | — | — | WO | disclosed |
| WO-2011162480-A9 | COMPOSITION FOR TREATING PRION DISEASES COMPRISING HIF-1Α AGONIST | 전북대학교산학협력단 (KR) | 2012-07-05 | — | — | WO | disclosed |
| WO-2011162480-A2 | COMPOSITION FOR TREATING PRION DISEASES COMPRISING HIF-1Α AGONIST | 전북대학교산학협력단 (KR) | 2011-12-29 | — | — | WO | disclosed |
| US-20100092546-A1 | Topical and Transdermal Delivery of HIF-1 Modulators to Prevent and Treat Chronic Wounds | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2010-04-15 | — | — | US | disclosed |
| US-20080213404-A1 | Hif Modulating Compounds and Methods of Use Thereof | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN DIEGO | 2008-09-04 | — | — | US | disclosed |
| WO-2006084210-A9 | HIF MODULATING COMPOUNDS AND METHODS OF USE THEREOF | UNIV CALIFORNIA SAN DIEGO (US) | 2006-10-26 | — | — | WO | disclosed |
| WO-2006084210-A2 | HIF MODULATING COMPOUNDS AND METHODS OF USE THEREOF | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN DIEGO (US) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080213404-A1 | Hif Modulating Compounds and Methods of Use Thereof | HIF1A, HIF1AN, EGLN3 | EGLN1 5/4885THRA 1637/4885THRB 2324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.